Anthrax and Bacterial Vaginosis Clinical Trials H2 2014 Global Review Reports

DALLAS, November 21, 2014 /PRNewswire/ --

RnRMarketResearch.com adds Bacterial Vaginosis Global Clinical Trials Review, H2, 2014 and Anthrax Global Clinical Trials Review, H2, 2014 market research reports to the clinical trials industry intelligence collection of its online library.

These Anthrax Global Clinical Trials Review, H2, 2014 and Bacterial Vaginosis Global Clinical Trials Review, H2, 2014 reports provide data on the anthrax and bacterial vaginosis clinical trial scenario, respectively. These reports provide elemental information and data relating to the clinical trials on bacterial vaginosis and anthrax. Each report includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating anthrax and bacterial vaginosis. These reports are built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

Note: Certain sections in these reports may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope of these global clinical trials review reports on Anthrax and Bacterial Vaginosis cover data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each. Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type as well as listings of discontinued trials (suspended, withdrawn and terminated) are covered in these reports.

Reasons to buy one or both of these global clinical trials review reports on Anthrax and Bacterial Vaginosis include understanding the dynamics of a particular indication in a condensed manner, getting an abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more, obtaining discontinued trial listing for trials across the globe and espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies.

Order a copy of Bacterial Vaginosis Global Clinical Trials Review, H2, 2014 market research report at http://www.rnrmarketresearch.com/contacts/purchase?rname=243504 and Anthrax Global Clinical Trials Review, H2, 2014 report is available for purchase at http://www.rnrmarketresearch.com/contacts/purchase?rname=243502 .

The Anthrax report covers latest clinical trial news like Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program and Soligenix Advances Development of a Heat Stable Rapidly Acting Anthrax Vaccine VeloThrax. Companies, universities and institutes / organizations discussed for their clinical trials in this Anthrax report include Emergent BioSolutions Inc., PharmAthene, Inc., Elusys Therapeutics, Inc., PaxVax, Panacea Biotec Limited, Human Genome Sciences, Inc. (Inactive), Green Cross Holdings Corporation, Defence Science and Technology Laboratory, Bavarian Nordic A/S, The National Institute of Allergy and Infectious Diseases, Fraunhofer Center for Molecular Biotechnology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Seoul National University Hospital, National Institutes of Health Clinical Center, Centers for Disease Control and Prevention, U.S. Department of Veterans Affairs and Duke University.

Symbiomix Therapeutics Makes First Corporate Announcement: Completion of Enrollment in a Phase 2 Clinical Trial of SYM-1219 for Bacterial Vaginosis is discussed in the bacterial vaginosis clinical trial report. Clinical trial overview of companies like Starpharma Holdings Limited, Symbiomix Therapeutics, LLC, Merck & Co., Inc., Ferring International Center S.A., AmVac AG, Osel Inc., Mission Pharmacal Company, Actavis plc, Arun Pharmaceuticals Limited and Alfa Wassermann S.p.A as well as those of top universities / government institutes like University of Alabama at Birmingham, University of Pittsburgh, Shiraz University of Medical Sciences, Lawson Health Research Institute, Centers for Disease Control and Prevention, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Mount Sinai Hospital, The National Institute of Allergy and Infectious Diseases and Ahvaz Jundishapur University of Medical Sciences are discussed in this research report.

Explore more reports on clinical trials industry as well as pharmaceuticals market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals .

About Us: 

RnRMarketResearch.com is an online database of market research reports and in-depth studies of over 5000 micro markets. Not limited to any one industry, we offer research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Contact:  

Ritesh Tiwari

TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252

Tel:  +1-888-391-5441
[email protected]

SOURCE RnR Market Research